Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yalda Nikanpour"'
Autor:
Masoud Etemadifar, Shadi Ghourchian, Nazanin Mahinparvar, Mehri Salari, Fatemeh Etemadifar, Yalda Nikanpour, Shahin Sanaei, Mojtaba Akbari
Publikováno v:
Acta Medica Iranica, Vol 57, Iss 8 (2020)
This study aimed to compare the efficacy of rituximab versus Cyclophosphamide on active secondary progressive multiple sclerosis (SPMS). The randomized clinical trial was performed from 2015 to 2017 in multiple sclerosis (MS) clinics affiliated to Is
Externí odkaz:
https://doaj.org/article/e4f007b3a4a74e729e945b7831199ac6
Autor:
Gian Marco Conte, W Oliver Tobin, Mana Moassefi, Shahriar Faghani, Paul Decker, Matthew Kosel, Yalda Nikanpour, Kuan Zhang, Daniel Honore Lachance, Robert Jenkins, Bradley Erickson, Jeanette Eckel-Passow
Publikováno v:
Neuro-Oncology. 24:vii181-vii181
Missing MRI sequences are common in radiology due to differences in protocols, time constraints, and image artifacts. Missing sequences are a nuisance for subsequent algorithms, such as automated segmentation algorithms requiring multiple MRI sequenc
Autor:
Shahin Sanaei, Nazanin Mahinparvar, Shadi Ghourchian, Mehri Salari, Fatemeh Etemadifar, Yalda Nikanpour, Mojtaba Akbari, Masoud Etemadifar
Publikováno v:
Acta Medica Iranica, Vol 57, Iss 8 (2020)
This study aimed to compare the efficacy of rituximab versus Cyclophosphamide on active secondary progressive multiple sclerosis (SPMS). The randomized clinical trial was performed from 2015 to 2017 in multiple sclerosis (MS) clinics affiliated to Is
Publikováno v:
Multiple Sclerosis and Related Disorders. 27:200-202
Tumors have been frequently reported to be associated with neuromyelitis optica (NMO). Here we review a case of a 34-year-old woman who presented with complaint of one-sided visual loss. All Lab tests exhibited negative results which decreased the po
Publikováno v:
Multiple sclerosis and related disorders. 40
Background There is an unapprehended diversity in the epidemiology of multiple sclerosis (MS) in different geographical regions. In this study, for the first time, we systematically review the studies estimating the incidence and/or prevalence of MS
Evidence to justify survival benefit of local therapy of the breast (LT) for breast cancer patients who are metastatic at presentation (MBC) is weak. The aim of this study is to evaluate the outcome of LT on survival in MBC patients. Patients who had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5bdd38ff36ae78768bde95ee2cbfba9
https://europepmc.org/articles/PMC6414585/
https://europepmc.org/articles/PMC6414585/